Navigation Links
Cardio Vascular Medical Device Launches Corporate Website
Date:11/11/2009

HAIFA, Israel, November 11 /PRNewswire-FirstCall/ -- Cardio Vascular Medical Device Corp. (OTC: CVSL), a leading developer of advanced cardiovascular surgery technology, today announced the completion of the company's corporate website located online at http://www.cvslmedical.com.

Cardio Vascular Medical Device holds a US patent for an innovative next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures. The guidewire has a unique opportunity to become the guidewire of choice for surgeons throughout the world.

The technology hinges on a bendable tip that improves guidewire performance, enables faster procedure completion, and provides cost benefits for patients as well as healthcare providers.

"Cardio Vascular Medical Device has developed a technology that provides several advantages over the current guidewires being employed in angioplasty procedures," stated Eli Gonen, CEO of Cardio Vascular Medical Device Corp. "And with well over 7 million angioplasties performed each year, the global annual potential addressable market exceeds $500 million."

Cardio Vascular Medical Device is working diligently to complete the development of the guidewire, in preparation for full commercial distribution.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Cardio Vascular Medical Device Corp. and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially fr
'/>"/>

SOURCE Cardio Vascular Medical Device Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
2. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
3. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
4. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
7. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
8. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
9. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
10. Cardiologists Tackle Next Frontier in Cardiovascular Disease
11. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)... Resources Group finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug ... billion in 2023 in the United States , ... Italy , Spain , the ... TNF-alpha inhibitors will remain the leading drug class in both sales ... constrained and patient shares will decline due to the uptake of ...
(Date:9/16/2014)... 16, 2014  Formex, LLC ("Formex"), a ... Mr. Greg Weilersbacher joined Formex as Director of ... Greg Weilersbacher has over ... expertise in Quality Assurance, Facility Validation, GMP ... brings to Formex a diverse wealth of ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... US Phase II Clinical Trials for Organ Transplantation, ... announces positive Phase I clinical results for,its transplantation ... clinical trials for organ transplantation. , Today LifeCycle ... I clinical trial program of LCP-Tacro, a,proprietary, once-daily ...
... Hemispherx Biopharma, Inc.,(AMEX: HEB), a biopharmaceutical company ... new drug entities for pandemic,disease threats, announced ... therapeutic product candidate Alferon-LDO in,combating highly pathogenic ... Alferon-LDO is a low-dose experimental oral formulation,of ...
Cached Medicine Technology:LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 2Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 4
(Date:9/16/2014)... abnormalities in the adrenergic and noradrenergic systems, both ... play a role in the development of post-traumatic ... no genetic evidence of this connection. A collaborative ... Mailman School of Public Health and the University ... gene and childhood adversity. For individuals with two ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Beginning October 1st ... a new service offering for its clients who book a ... the volume of business they buy. Most recurring visit ... during the work week, but others include clients whose unique ... pet sitter on a daily basis. The newly ...
(Date:9/16/2014)... 16, 2014 The Pain Center ... by Ranking Arizona magazine, has selected Analance ™, ... enterprise. , With TPC seeing hundreds of thousands ... repository that was managed through “home grown” systems trying ... and clinical leadership teams. “Our current tools were ...
(Date:9/16/2014)... 2014 Founded by former Miami Beach ... a political organization fighting to legalize medical marijuana in ... The After Party recently commissioned a shot-for-shot parody video ... from the movie “Grease.” ( http://youtu.be/zdcvhUgeDRg ) , Called ... the musical parody faithfully recreates the carnival scene made ...
(Date:9/16/2014)... 16, 2014 Synergy Research Group has ... gives the best detail and analysis of the state ... a variety of sources, including Ministry of Health in ... will give readers actionable intelligence on clinical trials in ... relied on by the local and international life science ...
Breaking Medicine News(10 mins):Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 3Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3Health News:Miami Beach Politician Drives 1,400 Miles to Texas to Shoot “Grease” Parody Video Supporting the Legalization of Medical Marijuana in Florida 2Health News:Synergy Research Group Debuts Ukraine Orange Paper 2
... , THURSDAY, Jan. 6 (HealthDay News) -- The ... death in newborn intensive care units (NICUs) would be eligible ... infants and young children, according to a new study. ... of the more than 200,000 people in the United States ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Jan. ... February 2007 must be reviewed by the U.S. Food and ... the agency announced Wednesday. This effort, one aspect of ... meant to keep more addictive products from the hands of ...
... non-profit organization focused on supporting innovative early career ... its fall Fellowship Award Committee review. The ... postdoctoral scientists conducting basic and translational cancer research ... the country. The Fellowship encourages the nation,s most ...
... Jan. 5 (HealthDay News) -- Women with multiple sclerosis are ... gene thought to be connected to the condition, a new ... more insight into the development of MS, which is becoming ... Although no one knows what causes MS, scientists suspect that ...
... lateral sclerosis (ALS), and frontotemporal lobar degeneration (FTLD) are ... that include an RNA-binding protein called TDP-43. This protein ... by these clumps. In a study published ... team led by Virginia M.-Y. Lee, PhD, director of ...
... China are reporting development of a less expensive, more eco-friendly ... it may be a more healthful form of water. Their ... Chemistry Research . Changgong Meng and Feng Huang ... a mixture of H2O and tiny amounts of D2O ...
Cached Medicine News:Health News:Infant Organ Donors Could Help Meet Transplant Needs: Study 2Health News:FDA Launches Review of Tobacco Products 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 4Health News:Study Sheds Light on Genetic Risk of MS 2Health News:Malfunctioning gene associated with Lou Gehrig's disease leads to nerve-cell death in mice 2
Stylet tube, endotracheal, sterile, stainless steel, malleable, one size, overall length 13"(33cm)....
SunGlide™ Stylette - Green Adult. Use in 7.0 to 10mm tubes. 25/box....
SunGlide™ Stylette - Blue Neonatal. Use in 2.0 to 3.5mm tubes. 25/box....
Disposable Aluminum Satin Finish E/T Stylette, Adult 16, 25/box....
Medicine Products: